A. Kher

发表

Adjusted Versus Fixed Doses of the Low-Molecular-Weight Heparin Fragmin in the Treatment of Deep Vein Thrombosis

M. Alhenc-Gelas, J. Fiessinger, M. Aiach, 1994, Thrombosis and Haemostasis.

Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery

J. Fricker, J. Cazenave, M. Wiesel, 1988, European journal of clinical investigation.

Long-term anticoagulant therapy in patients with coronary artery disease.

S. Husted, A. Kher, B. Ziegler, 2006, European heart journal.

A critical review of clinical trials for low‐molecular‐weight heparin therapy in unstable coronary artery disease

R. Becker, S. Husted, A. Kher, 2001, Clinical cardiology.

Low-Molecular-Weight Heparins: Weeks or Months Instead of Days of Treatment

A. Kher, M. Samama, 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Venous thromboembolism in the medically ill patient: a call to action

J. Bergmann, A. Kher, 2005, International journal of clinical practice.

Anticoagulation: The Old and the New

M. Samama, A. Kher, 1998 .

Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery.

J. Lerat, M. Dechavanne, B. Moyen, 1989, Haemostasis.

Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration.

M. Samama, L. Bara, E. Billaud, 1985, Thrombosis research.

Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects.

C. Soria, G. Simoneau, G. Tobelem, 1992, Thrombosis research.

Once-daily Subcutaneous Dalteparin, a Low Molecular Weight Heparin, for the Initial Treatment of Acute Deep Vein Thrombosis

J. Fiessinger, C. Olsson, S. Granqvist, 1996, Thrombosis and Haemostasis.

[Monitoring of heparin in the treatment of deep venous thrombosis. An obsolete question?].

A. Kher, F. Toulemonde, 1995, Annales de cardiologie et d'angeiologie.

[Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study].

B. Polack, J. Fiessinger, B. Boneu, 1989, La Revue de medecine interne.

Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients.

H. Dejour, M. Dechavanne, J. Faivre, 1975, Haemostasis.

Primary and secondary prophylaxis of venous thromboembolism with low‐molecular‐weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists

M. Samama, A. Kher, M. Samama, 2005, Journal of thrombosis and haemostasis : JTH.

Optimal Duration for Prophylaxis of Deep Vein Thrombosis: The New Focus?

A. Kher, F. Toulemonde, 1996 .

Spontaneous platelet aggregation in heparin-treated patients.

M. Samama, J. Conard, C. Lecrubier, 1984, Acta haematologica.

Effect of Standard Heparin and a Low Molecular Weight Heparin on Thrombolytic and Fibrinolytic Activity of Single-Chain Urokinase Plasminogen Activator In Vitro

M. Samama, D. Lourenço, A. Dosne, 1989, Thrombosis and Haemostasis.

Low-dose heparin in gynecologic surgery: effect on blood coagulation tests.

J. Conard, M. Samama, A. Kher, 1981, Haemostasis.

[Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].

M. Samama, I. Gouin, A. Kher, 2000, Annales de biologie clinique.

Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin.

M. Samama, L. Bara, E. Billaud, 1985, Seminars in Thrombosis and Hemostasis.

Ventricular Arrhythmias: A Double-Blind Placebo-Controlled Crossover Study

C. Libersa, J. Poirier, B. Dupuis, 2010 .

Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement

A. Kher, A. Kher, 2001, Expert opinion on investigational drugs.

The management of thrombosis in pregnancy: Role of low-molecular-weight heparin

R. Bauersachs, J. Nielsen, A. Kher, 2007, Thrombosis and Haemostasis.

Low Molecular Weight Heparin as Thromboprophylaxis in Pregnancy

A. Kher, T. Wahlberg, 1994 .

Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin.

M. Samama, A. Bendetowicz, A. Dosne, 1988, Thrombosis research.

[Prevention of thromboembolic complications in orthopedic surgery].

A. Kher, P. Barbier, J. Heilmann, 1988, The´rapie (Paris).